Avecho Biotechnology (ASX:AVE) said it has received AU$1.98 million for the year ended Dec. 31, 2025, under the Australian Government's research and development tax incentive scheme, according to a Friday Australian bourse filing.
The company said AU$1.62 million of the funds will be used to repay Endpoint Capital for advances on the company's R&D tax credit paid over the past year, with the remainder to support operations and advance its commercialization strategy.